Quan Dong Nguyen
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Quan Dong Nguyen sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Quan Dong Nguyen: 4 sponsored US clinical trials, 1 recruiting.
Quan Dong Nguyen sponsors 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cystoid Macular Edema, Postoperative, with 1 trials.
Upper-quartile sponsor footprint
Quan Dong Nguyen sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
Safety, Tolerability, and Distribution of Laquinimod Eye Drops : The LION Study
NCT06161415
Multicenter Study on the Efficacy and Safety of OCS-01 in Subjects With Uveitis Related and Post Surgical Macular Edema
NCT05608837
A Proof-of-concept Trial to EvaluAte the efficaCy and Safety Of Cell Therapy TRX103 in Patients With Active, Non-infectious Uveitis
NCT07427628
ACTH as A Re-emerging theRapy for Uveitis (The ACTHAR Study)
NCT02931175
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
Therapeutic Areas
What is open in the Quan Dong Nguyen pipeline
1 recruiting of 4 indexed (25% open); 1 completed (25%).
Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Cystoid Macular Edema, Postoperative (1 trial), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Quan Dong Nguyen: open-pipeline peers nationwide
Peers matched on 4 registered trials and 25% open enrollment, not the therapeutic-area sidebar.
Quan Dong Nguyen sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 25% open enrollment (± trial volume)
- AB Science · 25% recruiting · 8 trials
- Abbott Point of Care · 25% recruiting · 8 trials
- Accutar Biotechnology · 25% recruiting · 4 trials
- Adrienne G. Waks · 25% recruiting · 4 trials
Related
What to do with this Quan Dong Nguyen page
4 registered trials is a research-attention snapshot, not an endorsement of Quan Dong Nguyen or any single study.
- 1 of Quan Dong Nguyen's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Cystoid Macular Edema, Postoperative is the condition Quan Dong Nguyen studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cystoid Macular Edema, Postoperative trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Quan Dong Nguyen pipeline card: 4 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.